Skip to content
etf.net

Launched

Roundhill GLP-1 & Weight Loss ETF

OZEMNasdaqRoundhill InvestmentsC

$30.57−0.12 (−0.39%)

At close: Nov 2, 2026, 4:00 PM ET

C42/ 100

Rank 8 of 9 in Pharma & Therapeutics

C42/100Rank 8 of 9inPharma & Therapeutics
Intraday session: down, 79 prints from 30.70 to 30.57. Range 30.49 to 30.87. Use the arrow keys to read each point.30.5030.8010 AM12 PM2 PM4 PM
Expense ratio
0.59%
Fund size
$56M
1Y total return
+7.7%
Yield · Last 12 months
1.34%
Holdings
27
Avg volume · 30D
18.2K sh
52W range
low $28.34high $37.15
Launched

The ETF.net OZEM Grade

C

Score 42 out of 100

Category
Pharma & Therapeutics⁠
Rank
8 of 9
Six-pillar profile for OZEM. Scores out of 100: Cost 41, Risk 21, Mission 66, Tradability 25, Holdings 52, Durability 44. Strongest: Mission (66). Weakest: Risk (21). Leans toward Mission.

Score 42 of 100 falls in the C band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    C41 out of 100
    Rank 5 of 9

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    B66 out of 100
    Rank 4 of 6

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    F21 out of 100
    Rank 8 of 9

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    D25 out of 100
    Rank 7 of 9

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    C52 out of 100
    Rank 6 of 9

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    C44 out of 100
    Rank 7 of 9

Our read on OZEM

ETF.net Research

In short

CThe whole weight-loss trade in one ticker: roughly 30 stocks covering the drugmakers behind GLP-1 treatments plus the companies expected to benefit as use widens. Broad pharma funds bury this theme. OZEM is built entirely around it.

Stated mandate

The Fund seeks capital appreciation by providing exposure to companies developing pharmaceutical drugs for weight loss and anti-obesity, including GLP-1 treatments, as well as companies expected to benefit from their wider use.

Why people hold it

  • The mandate is explicit: companies developing weight-loss and anti-obesity drugs, including GLP-1s, plus firms expected to benefit from wider use. No hedging into general pharma.
  • A roughly 30-stock lineup means the theme actually drives the fund, rather than sitting as a small sleeve inside a diversified pharma basket.
  • At 0.59%, the fee sits in the same neighborhood as established pharma funds like PJP (0.57%) and FTXH (0.60%), despite the narrower, more specialized mandate.

Worth knowing

  • Broad pharma alternatives are cheaper: XPH at 0.35% and PPH at 0.36%. The theme focus here carries a price.
  • Thinly traded with a modest asset base, so spreads can be wide. Limit orders are the standard tool for funds in this range.
  • Launched in 2024, so the history is short, and a 30-stock single-theme basket swings on trial results and regulatory news at a handful of companies.

OZEM Performance

Launched May 21, 2024

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.Not enough history yet.Not enough history yet.
OZEM$10,772
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,146
Oct 31, 2025 to Nov 2, 2026. OZEM $10,772. SPY $11,146. Use the arrow keys to read each point.$10,000$11,000$12,000$13,000Oct 2025May 2026Nov 2026

Oct 31, 2025 – Nov 2, 2026

Returns run to the Nov 2, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for OZEM. Periods over one year show the average yearly return.
PeriodOZEM
Year to date−10.5%
1 month+2.2%
3 months−3.7%
1 year+7.7%
3 yearsFund is under 3 years oldper yearNo data
5 yearsFund is under 5 years oldper yearNo data
10 yearsFund is under 10 years oldper yearNo data

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for OZEM
YearReturn barOZEM
2026 YTD−10.5%
2025+41.9%
2024−3.8%

Since listing, May 21, 2024

OZEM in the news

OZEM Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Nov 2, 2026.
1.34%Last 12 months
Payout per share
$0.41Last 12 months
Last payment
$0.41 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Irregular

Distribution history

2024–2026

One bar per payment. 2 payments from 2024 to 2026 YTD. Dec 30, 2024 $0.05; Dec 30, 2025 $0.41. Use the arrow keys to read each point.202420252026YTD
Ex-datePay dateAmount per share
Dec 30, 2025Dec 31, 2025$0.41
Dec 30, 2024Dec 31, 2024$0.05

$10,000 in OZEM 1 year ago paid $141 in dividends.

OZEM Risk

Risk pillarF21 out of 100Rank 8 of 9 in Pharma & Therapeutics
How much the fund’s monthly returns vary, scaled to a year.
19.8%
Annualised · 29 months to Oct 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.34
vs 3-month T-bills · 29 months to Oct 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−28.6%
29 months · trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.47
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

OZEM Cost

Compare OZEM and PBPH

Overpaying vs PBPH, cheapest in Pharma & Therapeutics

$8,909

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • OZEM 0.59%

    $11,635

  • PBPH 0.13% Cheapest

    $2,726

$10,000
30 years

Cost over time

  • OZEM 0.59%
  • PBPH 0.13%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$2.5K$5K$7.5K$10K$12.5K051015202530OZEM $11,635PBPH $2,726

Year by year

YearOZEMPBPHOverpaying
10$1,058$238$820
20$4,051$930$3,121
30$11,635$2,726$8,909

Other funds in Pharma & Therapeutics

See others